
News|Articles|January 27, 2005
Warning Letter
Warning Letter
Advertisement
In a 7 January
As is typical in these warnings, the agency voicedconcerns that Essential is compounding not for individual patients butfor third-party resale, and that the compounded drugs duplicateapproved products in dosage and concentration.
Douglas McCormick
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Everything to Know about BMS & NVidia’s AI Supercomputer
2
Can AI Fix Pharma's Last-Mile Delivery Blind Spot?
3
From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026
4
Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data
5



